Oncomine Targeted NGS Assays for Oncology Research
Targeted sequencing with Oncomine NGS oncology assays
Oncomine™ assays are multi-biomarker targeted assays designed for cancer research. Enabling next-generation sequencing analysis of multiple biomarker types—fusions, insertion/deletions (indels), single nucleotide variants, and copy number variations—Oncomine assays are part of an end-to-end workflow that includes simple, scalable sequencing with Ion S5™ Series sequencers, and optimized bioinformatics and reporting with the Oncomine™ Knowledgebase Reporter.
Whether you are working with DNA or RNA, formalin-fixed, paraffin-embedded (FFPE) tissue samples, or blood, Oncomine assays engender trust among clinical cancer researchers because:
- Content includes cancer genes and is reviewed by experienced professionals to help ensure the highest relevancy
- Protocols and verification are based on analyses of clinical research samples to help ensure repeatable results
- Assays are produced under enhanced manufacturing quality control to facilitate consistent analyses across large sample sets
- Specialized application support teams are available to help enable faster implementation in your lab
Targeted NGS performance of Oncomine Assays and NCI-MATCH Trial Assay
The Oncomine Comprehensive Assay and NCI-MATCH Trial Assay* (based on the Oncomine Comprehensive Assay) have demonstrated robust performance even with very limited FFPE samples such as fine needle aspirates (FNA). Performance was evaluated through measures of reliability, sensitivity, specificity, and limit of detection.
Designed for concurrent DNA and RNA NGS analysis from FFPE samples. Targets 52 genes relevant to solid tumors. Detects SNVs, indels, CNVs, and fusions.
Designed for concurrent DNA and RNA NGS analysis from FFPE samples. Targets 143 cancer genes relevant to clinical cancer research. Detects SNVs, indels, CNVs, and fusions.
Tumor type-specific assays designed for NGS analysis from cell-free DNA. Targets genes relevant to lung, colon, and breast tumor samples. Detects SNVs and indels.
Powerful tools enabling complete NGS data analysis. Go from hundreds down to a few relevant cancer drivers in a report that enables contextual investigation of sample-specific variants.
Enables the detection of BRCA1/2 somatic mutations in FFPE tissue and germline mutations in whole blood.
Gene expression assay designed for superior performance in the detection of low-expressing genes from minimal FFPE RNA input. Targets 395 genes associated with immune response biomarker research.
With Ion Torrent™ next-generation sequencing (NGS) systems, you can analyze your sample for hundreds of variants of interest using a single sample in a single experiment. You can detect hotspots, SNVs, indels, CNVs, and gene fusions in a single run. For FFPE samples and liquid biopsy samples, both Ion AmpliSeq™ technology and Tag Sequencing technology enable results from as little as 1 ng of sample input.
With Ion Torrent NGS systems and Oncomine assays, your lab has the flexibility to scale and automate analyses to meet your sampling needs. Coupled with the Ion Chef™ System and the Ion S5 System, the Oncomine™ Focus Assay enables sample to refined variant data in as little as two days. And this same easy-to-use workflow achieves automated speed and simplicity to enable your lab technicians to run samples consistently.
Featured solution: Oncomine informatics
The Oncomine NGS oncology workflow enables you to find the relevant few cancer drivers. The comprehensive workflow includes powerful tools for cancer research, including a curated, verified knowledgebase that informs assay design, variant annotations to enhance your NGS data analysis, and a report that enables contextual investigation of sample-specific variants.
←The report header and footer contain many customizable fields. The Variant Summary presents the sample-specific data by source and variant. In the Relevant Therapy Summary, the easy-to-read legend continues as more details on each variant are presented.
For Research Use Only. Not for use in diagnostic procedures.